ArticleJournal of clinical microbiology2005
Genotyping of Madurella mycetomatis by selective amplification of restriction fragments (amplified fragment length polymorphism) and subtype correlation with geographical origin and lesion size.
Article in Journal of clinical microbiology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo.Medical mycology · 2023Article
- Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella.Medical mycology · 2022Article
- Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma.PLoS neglected tropical diseases · 2022Article
- The synthetic synergistic cinnamon oil CIN-102 is active against Madurella mycetomatis, the most common causative agent of mycetoma.PLoS neglected tropical diseases · 2021Article
- A Short-Tandem-Repeat Assay (Journal of clinical microbiology · 2021Article
- The development of a novel diagnostic PCR for Madurella mycetomatis using a comparative genome approach.PLoS neglected tropical diseases · 2020Article
- Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim.The Journal of antimicrobial chemotherapy · 2020Article
- The Accuracy of Histopathological and Cytopathological Techniques in the Identification of the Mycetoma Causative Agents.PLoS neglected tropical diseases · 2019Article
- Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma.PLoS neglected tropical diseases · 2018Article
- Mycetoma laboratory diagnosis: Review article.PLoS neglected tropical diseases · 2017Review
- A Madurella mycetomatis Grain Model in Galleria mellonella Larvae.PLoS neglected tropical diseases · 2015Article
- Association of eumycetoma and schistosomiasis.PLoS neglected tropical diseases · 2013Article
- In vitro antifungal activity of isavuconazole against Madurella mycetomatis.Antimicrobial agents and chemotherapy · 2012Article
- Subcutaneous fungal infections.Current infectious disease reports · 2012Article
- In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine.Antimicrobial agents and chemotherapy · 2011Article
- Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents.Antimicrobial agents and chemotherapy · 2010Article
- Phenotypic and molecular characterization of Madurella pseudomycetomatis sp. nov., a novel opportunistic fungus possibly causing black-grain mycetoma.Journal of clinical microbiology · 2010Article
- Molecular identification of black-grain mycetoma agents.Journal of clinical microbiology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the causative organisms of mycetoma is the fungus Madurella mycetomatis. Previously, extensive molecular typing studies identified Sudanese isolates of this fungus as clonal, but polymorphic genetic markers have not yet been identified. Here, we report on the selective amplification of restriction fragment (AFLP) analysis of 37 Sudanese clinical isolates of M. mycetomatis. Of 93 AFLP fragments generated, 25 were polymorphic, and 12 of these 25 polymorphic fragments were found in a large fraction of the strains. Comparative analysis resulted into a tree, composed of two main (clusters I and II) and one minor cluster (cluster III). Seventy-five percent of the strains found in cluster I originated from central Sudan, while the origin of the strains in cluster II was more heterogeneous. Furthermore, the strains found in cluster I were generally obtained from lesions larger than those from which the strains found in cluster II were obtained (chi-square test for trend, P = 0.03). Among the 12 more commonly found polymorphisms, 4 showed sequence homology with known genes. Marker A7 was homologous to an endo-1,4-beta-glucanase from Aspergillus oryzae, 97% identical markers A12 and B3 matched a hypothetical protein from Gibberella zeae, and marker B4 was homologous to casein kinase I from Danio rerio. The last marker seemed to be associated with strains originating from central Sudan (P = 0.001). This is the first report on a genotypic study where genetic markers which may be used to study pathogenicity in M. mycetomatis were obtained.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.